Compare Medtronic PLC (MDT) vs Teradyne, Inc. (TER) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medtronic PLC vs Teradyne, Inc. — how do they compare? Medtronic PLC trades at $90.58 (market cap $114.45B), while Teradyne, Inc. trades at $381.9 (market cap $57.08B). The key difference: Medtronic PLC is far larger — about 2× Teradyne, Inc.'s market cap, and Medtronic PLC pays the higher dividend (3.22%). Which is the better fit depends on your goals.
| MDT | TER | |
|---|---|---|
Market Cap | $114.45B | $57.08B |
Sector | Health | Technology |
52-Week High | $105.35 | $483.84 |
52-Week Low | $73.75 | $109.30 |
Enterprise Value | $133.19B | $56.83B |
Dividend Yield | 3.22% | 0.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $87.16, up 1.44% today, with a bullish technical signal and consistent earnings beats. The company reported Q1 2026 EPS of $1.55, exceeding expectations, and maintains solid fundamentals with a 13.2% net income margin and $33.54B in revenue for 2025. Recent news highlights growth in cardiac ablation and the Hugo robotic platform, with management guiding for 11.75% organic revenue growth in Q1 2027.
The outlook is positive, supported by analyst consensus of a $98.75 price target and 60% buy ratings. Key opportunities include dividend stability and innovation in medical technology, while risks involve rising debt levels and competitive pressures. The stock's current valuation at a P/E of 23.37 offers moderate upside if execution continues.
Teradyne (TER) trades at $379.31, down 1.45% today but maintains strong technical momentum with a bullish moving average signal. The company demonstrates robust fundamentals with record Q2 2026 earnings of $2.47 EPS beating estimates by 18%, driven by AI-led semiconductor test demand. Revenue grew to $3.19 billion in 2025 with impressive 25.77% net income margin and 36.66% ROE. Analyst consensus remains strongly bullish with 64.5% buy ratings and $481.63 price target representing 27% upside potential.
Teradyne presents compelling growth prospects fueled by AI-driven semiconductor testing demand and expanding robotics business. The stock trades at premium valuations (P/E 52.1, P/S 13.43) reflecting high growth expectations. Key risks include cyclical semiconductor industry exposure and execution challenges in scaling operations. Current technical positioning near pivot point ($384) suggests potential for breakout above resistance at $396 if earnings momentum continues through Q3 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →About Teradyne, Inc.
Teradyne provides testing equipment, including automated test equipment for semiconductors, system testing for hard disk drives, circuit boards, and electronics systems and wireless testing for devices. The firm entered the industrial automation market in 2015, into which it sells collaborative and autonomous robots for factory applications. Teradyne serves numerous end markets and geographies directly and indirectly with its products, but its most significant exposure is to semiconductor testing, which made up 71% of 2021 sales. Teradyne serves vertically integrated, fabless, and foundry chipmakers with its equipment.
Read more on TER →
